Drug combo before surgery for stage III lung cancer
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests a combination of three drugs (tislelizumab, anlotinib, and nab-paclitaxel) given before surgery for stage III lung cancer that can be removed. The goal is to see if this treatment helps shrink the tumor and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stage III non-small cell lung cancer that a surgeon believes can be removed completely.
- You have not received any previous treatment for this lung cancer (like chemo, radiation, or targeted therapy).
- Your tumor does not have EGFR or ALK gene mutations (or you have squamous cell lung cancer and haven't been tested for these).
- You are in generally good health (able to do daily activities) and have good organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining tumor ablation with the immunotherapy drug tislelizumab and chemotherapy before surgery for people with stage II–IIIB non-small cell lung cancer. The goal is to see if this combination helps remove the cancer more effectively.
This trial tests whether adding two newer drugs (benmelstobart and anlotinib) to chemotherapy before radiation works better than radiation alone for stage III non-small cell lung cancer that cannot be surgically removed. The goal is to improve survival and control the cancer.
This trial tests a combination of radiation, immunotherapy (QL1706), and chemotherapy given before surgery for non-small-cell lung cancer that can be removed. It aims to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of three drugs (tislelizumab, anlotinib, and standard chemotherapy) given before and after surgery for people with stage II to IIIB non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach can improve outcomes for patients who can have their tumor removed.
This trial tests combining chemotherapy with immunotherapy before surgery for people with stage III non-small cell lung cancer that has a PD-L1 level of 1% or higher. The goal is to see if this approach can improve outcomes.
This trial tests a combination of immunotherapy (tislelizumab) followed by surgery and radiation for people with a specific type of advanced lung cancer (N3 stage NSCLC). The goal is to see if this approach can shrink tumors and improve outcomes.
Hear when a new Tislelizumab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.